98-26082. Medical Devices; Exemptions From Premarket Notification; Class II Devices  

  • [Federal Register Volume 63, Number 189 (Wednesday, September 30, 1998)]
    [Notices]
    [Pages 52275-52276]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 98-26082]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    [Docket Nos. 98P-0425, 98P-0506, and 98P-0621]
    
    
    Medical Devices; Exemptions From Premarket Notification; Class II 
    Devices
    
    Agency: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is publishing a list of 
    petitions requesting exemption from the premarket notification 
    requirements for certain class II devices. FDA is publishing this 
    notice in order to obtain comments on these petitions in accordance 
    with procedures established by the Food and Drug Administration 
    Modernization Act of 1997 (FDAMA).
    
    DATES: Written comments by October 30, 1998.
    
    ADDRESSES: Submit written comments on this notice to the Dockets 
    Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers 
    Lane, rm. 1061, Rockville, MD 20852.
    
    FOR FURTHER INFORMATION CONTACT: Heather S. Rosecrans, Center for 
    Devices and Radiological Health (HFZ-404), Food and Drug 
    Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-
    1190.
    
    SUPPLEMENTARY INFORMATION:
    
    I. Statutory Background
    
        Under section 513 of the Federal Food, Drug, and Cosmetic Act (the 
    act) (21 U.S.C. 360c), FDA must classify devices into one of three 
    regulatory classes: Class I, class II, or class III. FDA classification 
    of a device is determined by the amount of regulation necessary to 
    provide a reasonable assurance of safety and effectiveness. Under the 
    Medical Device Amendments of 1976 (the 1976 amendments (Pub. L. 94-
    295)), as amended by the Safe Medical Devices Act of 1990 (the SMDA 
    (Pub. L. 101-629)), devices are to be classified into Class I (general 
    controls) if there is information showing that the general controls of 
    the act are sufficient to assure safety and effectiveness; into class 
    II (special controls), if general controls, by themselves, are 
    insufficient to provide reasonable assurance of safety and 
    effectiveness, but there is sufficient information to establish special 
    controls to provide such assurance; and into class III (premarket 
    approval), if there is insufficient information to support classifying 
    a device into class I or class II and the device is a life-sustaining 
    or life-supporting device or is for a use which is of substantial 
    importance in preventing impairment of human health, or presents a 
    potential unreasonable risk of illness or injury.
        Most generic types of devices that were on the market before the 
    date of the 1976 amendments (May 28, 1976) generally referred to as 
    preamendment devices) have been classified by FDA under the procedures 
    set forth in section 513(c) and (d) of the act through the issuance of 
    classification regulations into one of these three regulatory classes. 
    Devices introduced into interstate commerce for the first time on or 
    after May 28, 1976 (generally referred to as postamendment devices) are 
    classified through the premarket notification process under section 
    510(k) of the act (21 U.S.C. 360(k)). Section 510(k) of the act and the 
    implementing regulations, 21 CFR part 807, require persons who intend 
    to market a new device to submit a premarket notification report 
    (510(k)) containing information that allows FDA to determine whether 
    the new device is ``substantially equivalent'' within the meaning of 
    section 513(i) of the act to a legally marketed device that does not 
    require premarket approval.
        On November 21, 1997, the President signed into law FDAMA (Pub. L. 
    105-115). Section 206 of FDAMA, in part, added a new section 510(m)(1) 
    of the act which requires FDA, within 60 days after enactment of FDAMA, 
    to publish in the Federal Register a list of each type of class II 
    device that does not require a report under section 510(k) of the act 
    to provide reasonable assurance of safety and effectiveness. Section 
    510(m) of the act further provides that a 510(k) will no longer be 
    required for these devices upon the date of publication of the list in 
    the Federal Register. FDA published that list in the Federal Register 
    of January 21, 1998 (63 FR 3142).
        Section 510(m)(2) of the act provides that, 1 day after the date of 
    publication of the list under section 510(m)(1), FDA may exempt a 
    device on its own initiative or upon petition of an interested person, 
    if FDA determines that a 510(k) is not necessary to provide reasonable 
    assurance of the safety and effectiveness of the device. This section 
    requires FDA to publish in the Federal Register a notice of intent to 
    exempt a device, of the petition, and to provide a 30-day comment 
    period. Within 120 days of publication of this document, FDA must 
    publish in the Federal Register its final determination regarding the 
    exemption of the device that was the subject of the notice. If FDA 
    fails to respond to a petition under this section within 180 days of 
    receiving it, the petition shall be deemed granted.
    
    II. Criteria for Exemption
    
        There are a number of factors FDA may consider to determine whether 
    a 510(k) is necessary to provide reasonable assurance of the safety and 
    effectiveness of a class II device. These factors are discussed in the 
    guidance the agency issued on February 19, 1998, entitled ``Procedures 
    for Class II Device Exemptions from Premarket Notification, Guidance 
    for Industry and CDRH Staff.'' That guidance can be obtained through 
    the World Wide Web on the CDRH Home Page at ``http://www.fda.gov/cdrh'' 
    or by facsimile through CDRH Facts-on-Demand at 1-800-899-0381 or 301-
    827-0111. Specify ``159'' when prompted for the document shelf number.
    
    III. List of Petitions
    
        FDA has received the following petitions requesting an exemption 
    from premarket notification for class II devices:
    
    [[Page 52276]]
    
        1. Abbott Laboratories, 21 CFR 862.1715 Triiodothyronine uptake 
    test system devices.
        2. Radiological Imaging Technology, 21 CFR 892.5050, Film Dosimetry 
    System, a.k.a. Film Scanning System.
        3. Getinge/Castle, Inc., 21 CFR 878.4580 Surgical Lamps.
    
    IV. Comments
    
        Interested persons may, on or before October 30, 1998, submit to 
    the Dockets Management Branch (address above) written comments 
    regarding this notice. Two copies of any comments are to be submitted, 
    except that individuals may submit one copy. Comments are to be 
    identified with the docket number found in brackets in the heading of 
    this document. The petitions and received comments may be seen in the 
    office above between 9 a.m. and 4 p.m., Monday through Friday.
    
        Dated: September 23, 1998.
     William B. Schultz,
     Deputy Commissioner for Policy.
    [FR Doc. 98-26082 Filed 9-29-98; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
09/30/1998
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
98-26082
Dates:
Written comments by October 30, 1998.
Pages:
52275-52276 (2 pages)
Docket Numbers:
Docket Nos. 98P-0425, 98P-0506, and 98P-0621
PDF File:
98-26082.pdf